Concepedia
Statistics
Publications
28
Citations
3.1K
H-Index
22
Active since
1969
Affiliations
Bristol-Myers Squibb (United States)(Current)
Biohaven Pharmaceuticals (United States)
Albert Einstein College of Medicine
King's College London
Wellcome Trust
David Stock is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, pharmacotherapy, and medicine.
Publications per year
1969–2023
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
Richard B. Lipton, Robert Croop, Elyse Stock et al. · New England Journal of Medicine · 2019 · 396 citations · Full text
Pharmacy, Pharmacology, Pharmacotherapy +14
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Robert Croop, Peter J. Goadsby, David Stock et al. · The Lancet · 2019 · 392 citations
Pharmacy, Pharmacology, Pharmacotherapy +12
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
Robert Croop, Richard B. Lipton, David Kudrow et al. · The Lancet · 2020 · 351 citations
Pharmacy, Neurology, Pharmacotherapy +12
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
Ronald N. Marcus, Peter J. Goadsby, David W. Dodick et al. · Cephalalgia · 2013 · 292 citations
Medicine, Pharmacology, Pharmacotherapy +16
4-Thiazolidinones: novel inhibitors of the bacterial enzyme murB
Charles J. Andres, Joanne J. Bronson, Stanley V. D’Andrea et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 220 citations
Life Sciences, Medicinal Chemistry, Microbiology +9
1–5 of 28